MA-VERACODE
2.4.2024 09:31:35 CEST | Business Wire | Press release
Veracode, a global leader in application risk management, today announced the acquisition of Longbow Security, a pioneer in security risk management for cloud-native environments. The acquisition marks the next exciting phase of Veracode, underscoring the company’s commitment to help organizations effectively manage and reduce application risk across the growing attack surface.
The integration of Longbow into Veracode enables security teams to discover cloud and application assets quickly and easily assess their threat exposure using automated issue investigation and root cause analysis. Longbow provides a centralized view of risk for cloud assets and applications, thereby simplifying complex workflows, enabling faster and more effective remediation, and improving overall security posture. The result is reduced risk and fewer vulnerabilities in applications and cloud infrastructures.
Increased adoption of cloud infrastructure, combined with developers taking on more responsibility for the creation, deployment, and security of software, has introduced operational complexity. Organizations now require a deeper understanding of their risk profile within changing environments and a continuous security feedback loop throughout the software development life cycle.
“Security teams are drowning in alerts that lack sufficient detail on the level of business risk, degree of exploitability of a flaw, and specific code-level insight to keep pace with remediation requirements. As a result, risk continues to accumulate,” said Brian Roche, Chief Product Officer at Veracode. “With the combination of Veracode and Longbow, teams can get a comprehensive view of their risk, automate prioritization of what matters most, and, with Veracode Fix, automate remediation of code security flaws.”
Longbow and Veracode Simplify Cloud Application Security for Overloaded Teams
With 71 percent of organizations shouldering the burden of “security debt” (flaws in applications that remain unfixed for one year), teams must act quickly to reduce their threat exposure. Yet, sufficient visibility and alert fatigue continue to plague cloud and application security professionals today. With Longbow, Veracode customers can address these challenges in four ways:
- Unified visibility of risk across applications, code, and cloud. This gives teams insight to tackle significant issues that matter most to the business.
- Orchestrated remediation from code to cloud, enabling teams to prioritize and remediate with Veracode’s AI-driven fix capabilities.
- Actionable insights with ‘Best Next Action’ advice, so customers can conduct a root cause analysis and pinpoint the best path to remediation.
- Continuous monitoring and assessment via real-time vulnerability discovery across application portfolios and runtime environments, meaning customers know exactly what is running and where.
Derek Maki, Co-Founder & Chief Product Officer at Longbow said, “We founded Longbow with a mission to simplify an increasingly complex application security risk management process and help organizations reduce risk at scale. By joining forces with Veracode, our combined solutions provide unmatched visibility, automation, and remediation capability for security and engineering teams. We are excited to take cloud-native application security to the next level.”
“This is the perfect fit for Longbow,” said Dayne Myers, Co-founder & Chief Executive Officer of Longbow. “After careful consideration, we believe that our technology and team align seamlessly with Veracode's vision, making this the best choice for Longbow’s future."
“We’re thrilled to welcome Longbow to Veracode and expand our platform capabilities with industry-leading application security posture management for today’s enterprise requirements,” closed Sam King, Chief Executive Officer at Veracode. “The integration of our solutions provides organizations with a holistic application risk management platform that spans code to cloud. Veracode combined with Longbow advances the field of application security and enables customers to secure their increasingly complex application landscape more efficiently.”
Longbow is available immediately. To learn more about the platform, visit the Longbow website. Read the blog for information on the acquisition.
About Veracode
Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Using powerful AI trained on a carefully curated, trusted dataset from experience analyzing trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401671481/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
